Medical Communications

Showing 15 posts of 6408 posts found.

findacure

Drug repurposing can help tackle Rare Diseases, says charity

February 29, 2016 Medical Communications, Research and Development, Sales and Marketing rare diseases

On Rare Disease Day 2016, UK charity Findacure says existing drugs may hold the key to new treatments and repurposing …
boehringer_good

Boehringer launches IPF initiatives

February 29, 2016 Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Esbriet, Roche, idiopathic pulmonary fibrosis, ofev

Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …

INTERVIEW: AstraZeneca on the Cancer Drugs Fund reforms

February 26, 2016 Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund

Greg Rossi, head of the Oncology Business Unit, AstraZeneca UK and Ireland, and the company’s market access team, spoke to …
baumann_bayer

Bayer names Werner Baumann new CEO

February 26, 2016 Medical Communications Bayer

Werner Baumann will become the new chief executive of Bayer AG from May 1, the company has announced. The decision …

Obama announces acceleration of Precision Medicines Initiative

February 26, 2016 Medical Communications, Research and Development Obama, Precision Medicine, cancer moonshot, genomics

A year after Barack Obama announced the $200 million Precision Medicines Initiative (PMI), the US President yesterday outlined the next …
msd

MHRA approves new indication for MSD’s Ezetrol

February 26, 2016 Medical Communications, Research and Development, Sales and Marketing MHRA, MSD, NICE, ezetrol

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for MSD’s Ezetrol (ezetimibe), making it …
nhs_sign

NHS England approves Cancer Drugs Fund proposals

February 26, 2016 Medical Communications, Research and Development ABPI, Cancer Drugs Fund, NHS England

NHS England has approved proposed reforms of the Cancer Drugs Fund, following the end of the 12-week consultation period earlier …
gilead-sciences

Gilead announces HIV regimen trial results

February 25, 2016 Medical Communications, Research and Development, Sales and Marketing Gilead Sciences

Gilead Sciences has reported 48-week Phase III trial results suggesting fixed-dose Emtriva and tenofovir alafenamide (F/TAF) combinations matched its Truvada …
dr_robert_califf_fda

Senate confirms Dr Robert Califf to lead FDA

February 25, 2016 Medical Communications Drug pricing, FDA, Robert Califf

The US Senate has confirmed Dr Robert Califf as Commissioner of the Food and Drugs Administration, in an overwhelming 89-4 …
howard_schiller_valeant

Valeant likely to restate financial results after Philidore review

February 23, 2016 Manufacturing and Production, Medical Communications, Sales and Marketing Howard Schiller, Philidore, Valeant

Valeant says it is likely to restate its financial results for the last two years, in the wake of the …
viiv_healthcare

ViiV completes BMS HIV pipeline purchase

February 23, 2016 Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, GSK, HIV, Pfizer, Shionogi, ViiV

ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …
fda

Califf clears key hurdle to FDA top job

February 23, 2016 Manufacturing and Production, Medical Communications, Research and Development

Dr Robert Califf, President Obama’s nominee to head up the US Food and Drugs Administration as commissioner, has edged a …
pharmafocus_march_front_cover

March edition of Pharmafocus live

February 22, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

The March 2016 edition of Pharmafocus is now live and available to read here.
amgen_ucb

Amgen and UCB announce positive romosozumab results

February 22, 2016 Medical Communications, Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, osteoporosis

Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …
sarah_opendi_and_rasha_kelej_at_the_campaigns_launch

Merck launches infertility programme in Uganda

February 22, 2016 Medical Communications, Sales and Marketing Merck Serono

Germany’s Merck has extended its infertility programme ‘Merck More than a Mother’ to Uganda, launching the campaign in a second …
The Gateway to Local Adoption Series

Latest content